The incidence of skin and soft-tissue infections (SSTIs) in the United States increased sharply in the hospital setting and among outpatients after 2000 [1] [2] [3] [4] . SSTIs include a range of conditions from uncomplicated folliculitis, skin abscess, or cellulitis to severe, life-threatening infections, such as necrotizing fasciitis. In the period 1993-2005, US emergency department (ED) visits related to SSTIs increased dramatically [5] , particularly in urban EDs [6] . This increase coincided with, and is often attributed to, a sharp increase in community-associated (CA) methicillin-resistant Staphylococcus aureus (MRSA) infections [7] [8] [9] [10] . Compounding this increase, among patients who present with a CA-MRSA SSTI, >30% have a recurrent infection diagnosed within 1 year [11] [12] [13] . In 2004 and 2008, MRSA was the most common cause of purulent SSTIs among patients treated at 12 US urban EDs [14] .
Data from the National Hospital Ambulatory Medical Care Survey demonstrated that approximately 6.8 million ED visits for SSTIs occurred in the United States in 2007-2009 [15] , and that the number of ED visits for SSTIs increased from 3.55 million in 2007 to 4.21 million in 2010 [16] . Although several studies have suggested that the incidence of MRSA infections has decreased in the United States after 2005 [17, 18] , and we demonstrated a decreasing overall trend in the rate of SSTIs at the University of Chicago in 2006-2013 [19] , few published data are now available about the epidemiology of SSTIs in US EDs after 2010.
Furthermore, although human immunodeficiency virus (HIV) infection is a risk factor for MRSA SSTIs [20, 21] , few large studies have examined the recent incidence of SSTIs among persons with HIV infection. In particular, the longitudinal trends on SSTI incidence in ED patients with HIV infection are not known, despite the fact that many HIV-infected patients receive their urgent care in EDs.
We noticed that there was a decline in the number of patients visiting our ED with uncomplicated SSTIs after 2012. We therefore examined temporal trends in SSTI rates among ED patients in 2009-2014 at 86 US academic medical centers. We hypothesized that the incidence of SSTIs overall and among patients with HIV infection decreased significantly.
clinical and administrative data related to patient encounters at member academic medical centers in the United States. Data were obtained for all ED encounters at 86 academic medical centers between 1 January 2009 and 31 December 2014, and, among them, the cohort of encounters with a diagnosis of SSTI. SSTI encounters were defined as having, in administrative records, at least a single SSTI-associated International Classification of Diseases, Ninth Revision (ICD-9) code (see Supplementary  Table 1 ). An encounter was considered an ED encounter if a subject visited an ED and was not admitted to the hospital. We included only the first ED encounter for an SSTI for each individual subject in a calendar year. The University of Chicago Biological Sciences Division Institutional Review Board approved the study.
Demographic Characteristics
In this retrospective cohort study, variables collected for each patient encounter included age, ethnicity, race, insurance payer type, region of the United States, HIV status (defined as having a primary or secondary diagnosis ICD-9 code of 042), and all other comorbid conditions noted in ICD-9-coded data. Patients were categorized as either pediatric (<18 years of age) or adult (≥18 years of age). Hispanic, African American, white, or other race (a category that included those reported >1 race, those who declined to answer, and unknown) was self-reported by each patient. Payer type was defined as low socioeconomic status (SES) (a category that included Medicaid, charity care, county medical indigent, and self-pay uninsured), commercial (purchased through a for-profit insurance provider), Medicare, or other (a category that included, but was not limited to, workers compensation, auto insurance, federal employee coverage, self-pay cash, unknown, state insurance programs, and criminal justice coverage). A region of care assigned to each patient was defined by medical center location: West, Midwest, Northeast, or South in the United States (Supplementary Figure 1) . A patient was considered to have a comorbid condition if he or she had an ICD-9 code for any medical problem other than the SSTI.
Analysis
Incidence densities (hereafter referred to as "rates") of both HIV infection and SSTIs were calculated by year. The SSTI rates were calculated separately for all encounters and then among those with and those without an HIV ICD-9 code. We first performed individual unadjusted Poisson regression analyses for each year, age group (pediatric or adult), ethnicity/race, payer type, and region of residence. Multivariable Poisson regression models, controlling for covariates, were then used to assess (1) the change in SSTI incidence over time among all patients, (2) the change over time in those with an HIV encounter, (2) the differential rate of SSTIs in those with versus those without HIV infection, and (3) the differential rate of SSTIs in those with versus those without comorbid conditions. All covariates identified as statistically significant at the P ≤ .05 level, using the Wald test statistic, were included in the multivariable regression model (including comorbid conditions, age, race, payer type, and region of residence). Analyses were performed using Stata 14.0 software (StataCorp) [22] .
RESULTS
During the study period, from January 2009 through December 2014, data were collected for 25 838 647 ED patient encounters across 86 academic medical centers. Among all ED patient encounters, 820 441 (3.18%) had an ICD-9 code for SSTI as a primary or secondary diagnosis, with a rate of 31.8 SSTIassociated encounters per 1000 ED patient encounters. In the study cohort, 47 317 patient encounters (0.18%) had an ICD-9 code for HIV, with a rate of 1.9 HIV-associated encounters per 1000 patient encounters. Nearly half of SSTI encounters involved white patients (49.3%), and about one-third involved African American patients (29.1%). Commercial insurance covered 27.5% of all ED encounters, but only 24.1% of SSTI ED encounters. Among 4 966 652 pediatric ED encounters, 113 222 (2.2%) were for SSTIs. The total number of ED encounters increased in each year. Data on the demographics of patients with ED encounters overall and the number of SSTI ED encounters, as well as the distribution of ED encounters by region of the United States and by year, are shown in Table 1 .
The overall rate of SSTIs decreased significantly, from 32. Patients whose payer was commercial (RR, .99; 95% CI, .99-1.00), low SES (0.98; .98-.98), or Medicare (0.99; .98-.99) had significantly reduced SSTI rates, whereas those with another payer type had a significantly increased rate (1.01; 1.01-1.02). It was also observed that the SSTI rates decreased across all regions of the United States (Table 2) .
SSTI rates differed between patients with and those without HIV infection, with 32.5 SSTI-associated encounters per 1000 ED encounters in HIV-uninfected patients, compared with 51.9 SSTI-associated encounters per 1000 ED encounters in HIV-infected patients. This pattern was observed across the study period, with SSTI rates among those with HIV infection consistently higher than among all ED encounters ( Figure 1) . Furthermore, among all ED encounters there was a consistent and strong seasonal peak in the second quarter of each year.
In separate sensitivity analyses, we examined SSTI rates in those with versus those without additional comorbid conditions among (1) the entire sample, (2) adults only, and (3) pediatric patients only. We observed a significant decrease in the SSTI rate in both those with (RR, 0.99; 95% CI, .99-.995) and those without (0.99; .98-.99) other comorbid conditions. In adults, we continued to observe a significant decrease in those with (RR, 0.99; 95% .99-.996) and those without (0.98; .98-.98) comorbid conditions. In pediatric patients, however, we observed a significant decrease in those with comorbid conditions (RR, 0.98; 95% CI, .97-.99) and a significant increase in those without any comorbid conditions (1.01; 1.004-1.01).
Among HIV-associated ED encounters, the majority of patients (Table 3) did not have an SSTI-associated encounter (94.8%), were adults (98.7%), were African American (56.2%), and had a payer type of low SES (55.3%). The greatest proportion received care in the South (34.0% 
DISCUSSION
We studied >25 million ED patient encounters across 86 academic medical centers to assess our research questions. We found that during 2009-2014, the rate of all ED SSTI encounters decreased by 8.0%. HIV-associated ED SSTI encounters also decreased significantly, by 14.6%. This is a major reversal of the great increase in SSTI incidence in the United States in outpatient and inpatient care settings after the year 2000, with the emergence of the USA300 MRSA strain [5] [6] [7] [8] [9] [10] 14] . We observed a significant decrease in SSTI rates in the following groups: adult patients with HIV-associated encounters; all adults; African American, Hispanic, and white patients; patients whose payer was commercial, low SES, or Medicare; and patients in all regions of the United States. We also observed significantly higher SSTI rates in HIV-infected patients than in those with non-HIV-associated encounters, adjusting for demographic group, payer type, and region. Recent research examining temporal trends in the incidence of both MRSA infections and SSTIs has demonstrated a decline in both after approximately 2005 [17, 19, 23 ]. In the current study, we observed a significant decrease in the rate of SSTIs in many demographic risk groups. Children were the only demographic group in which we observed an increase in SSTI rate, but further analyses demonstrated that this increase occurred only in children without other comorbid conditions. These results suggest that the rising rate in this cohort is most likely to due to community-associated infections, not healthcare-associated infections. We also observed that, compared with non-HIV-associated encounters, HIV-associated encounters had a significantly higher SSTI rate. Past research has demonstrated a high prevalence of SSTIs in men who have sex with men (MSM) caused by multidrug-resistant USA300 [24] , and physicians should be aware of CA-MRSA as a potential cause of SSTI in HIV-infected individuals [25] .
More generally, SSTIs have been shown to be common in HIV-infected patients [26] . A high rate of SSTI recurrence (71%) has also been found in the primary care setting among HIV-infected patients in San Francisco [27] and HIV-infected patients in Chicago [28] . Although an overall decline in the rate of SSTIs was observed in this sample, we continued to observe a higher rate in those who were HIV-infected. It is possible that there are differing incidence rates of SSTIs in MSM or other HIV transmission risk groups, independent of HIV infection status. Future research is necessary to define the reasons for the observed trends in SSTI incidence in these high-risk groups and the role of recurrent infections in the epidemiology of SSTIs. Overall in the United States, the rate of new HIV diagnoses has decreased 19% over the past decade, although this rate varies by both demographic and risk groups [29] . Although the rate of new HIV diagnoses has decreased in both men and women, MSM and African American men and women continue to be disproportionately affected by HIV [29] . Furthermore, both Hispanic and African American MSM are among the only demographic and risk groups to have experienced an increase in the incidence of new HIV infections in 2009-2014, with younger Hispanic and African American MSM (those aged 13-24 years) experiencing the steepest increases in the rate of new diagnoses [29] .
This study should be viewed in the context of its limitations. We used administrative data and ICD-9 codes to identify both HIV-and SSTI-associated ED patient encounters. Since the study period, the International Classification of Diseases, Tenth Revision (ICD-10), has replaced ICD-9, and future studies must account for changes that will result from coding practices with ICD-10. Our study was performed with data only from academic medical centers, and thus trends that we identified may not be true of all US medical facilities. Although these data have high sensitivity, they have a lower specificity for identifying subjects with an SSTI or HIV infection than do medical records. In addition, though we used a large and robust data set, we are missing data that would be useful in exploring trends in SSTI infections among HIV-infected patients, particularly transmission risk group characteristics.
In our study, we demonstrated an overall decrease in the incidence of SSTIs among all patients at US academic medical centers, a trend that reverses a massive increase in SSTI incidence after 2000. Patients with HIV-associated ED encounters similarly showed a decrease in SSTI incidence. We also observed higher SSTI rates among those who were HIV infected, compared with those who were not, across all demographic groups, payer types, and regions of the United States. The higher incidence of SSTIs in HIV-infected patients represents a substantial burden of disease, and this should be addressed in future, prospective studies on the prevention of SSTIs in this population.
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